Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: Results of the ECAPTURE study

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 6, 2001, Pages 453-458

  De Maat, M P M ^a,b,c   Dooijewaard, G ^a   Meijer, P ^a   Binder, B R ^d   Keber, D ^e   Risberg, B ^f   Kluft, C ^a,b,c   Jespersen, J ^b,c  

^a TNO   (Netherlands)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ESBJERG HOSPITAL   (Denmark)

^d UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angina; Myocardial infarction; Population; Urokinase

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; PROUROKINASE; UROKINASE; UROKINASE RECEPTOR;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOSIS;

ANGINA PECTORIS; ANGIOGRAPHY; CARDIOVASCULAR DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY CONTROL; REFERENCE VALUES; RISK FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034869106     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200109000-00005     Document Type: Article

References (20)

1. The role of fibrinolysis in disease processes
2. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
3. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men
4. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
5. The haemostatic balance - Astrup revisited
6. Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: A randomized placebo-controlled trial
7. Depression of factor XII-dependent fibrinolytic activity characterizes patinets with early myocardial reinfarction after recombinant tissue-type plasminogen activator therapy
8. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained
9. The rationale of prevention of thrombosis by enhancing blood levels of single-chain urokinase-type plasminogen activator (scu-PA)
10. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation
11. Urokinase plasminogen activator system in humans with stable coronary artery disease
12. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis
13. Blood collection and sample preparation: Pre-analytical variation
14. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA
15. Quantitation of pro-UK, UK and UK-inhibitor levels in plasma of patients and healthy man
16. Heterogeneous distribution of macrophages, tumour necrosis factor alpha, tissue factor and fibrinolytic regulators in atherosclerotic vessels
17. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system
18. The dual role of the urokinase receptor system in pericellular proteolysis and cell adhesion: Implications for cardiovascular function
19. Urokinase plasminogen activator system in humans with stable coronary artery disease
20. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery